Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632332 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01632332: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01632332 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01632332, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL HER-2/neu peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-07-09 |
| Est. Completion | 2018-07-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01632332
The ClinicalTrials.gov registry entry for NCT01632332 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01632332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01632332 about?
NCT01632332 is a clinical study titled "Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer". The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer.
What is the current status of trial NCT01632332?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2012-07-09. Estimated completion is 2018-07-09.
What interventions are being tested in trial NCT01632332?
The interventions under investigation include: laboratory biomarker analysis (OTHER), HER-2/neu peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01632332?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.